120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
纳米医学介导的肺癌光动力治疗进展：挑战与展望
Authors Liao Y, Zhang S, Liu Y , Li F, Zhang G, Liu H
Received 14 September 2025
Accepted for publication 15 December 2025
Published 17 January 2026 Volume 2026:21 567599
DOI https://doi.org/10.2147/IJN.S567599
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Kamakhya Prakash Misra
Yumei Liao,1 Shiyu Zhang,1 Yan Liu,2 Fengye Li,1 Gongjun Zhang,1 Hai Liu2
1Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, People’s Republic of China; 2College of Pharmacy, Gannan Medical University, Ganzhou, People’s Republic of China
Correspondence: Gongjun Zhang, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, People’s Republic of China, Email zhanggj@gimi.ac.cn Hai Liu, College of Pharmacy, Gannan Medical University, Ganzhou, People’s Republic of China, Email liuhaiuser@163.com
Abstract: Photodynamic therapy (PDT), a precision modality based on photosensitizers, light, and oxygen, demonstrates unique advantages in lung cancer treatment. The limitations of traditional photosensitizers in clinical applications, including poor water solubility and insufficient targeting, have driven the development of nanotechnology and novel photosensitizers. Accordingly, this review elaborates on advanced strategies designed to enhance therapeutic specificity and efficacy, overcome the hypoxic tumor microenvironment (TME) and combat monotherapy resistance. These strategies include the design of various nanocarriers, active targeting ligands, novel energy transfer methods, as well as intelligent responsive systems and combination therapies. Nevertheless, despite abundant preclinical achievements, the clinical translation of nano-PDT formulations faces significant obstacles. Future efforts should focus on developing theranostic platforms to rigorously evaluate clinical safety and efficacy, enable precision treatment, and decipher immunological synergy.
Keywords: photodynamic therapy, nanomedicine, targeting ligands, responsive design, lung cancer
1Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, People’s Republic of China; 2College of Pharmacy, Gannan Medical University, Ganzhou, People’s Republic of China
Correspondence: Gongjun Zhang, Gannan Innovation and Translational Medicine Research Institute, Gannan Medical University, Ganzhou, People’s Republic of China, Email zhanggj@gimi.ac.cn Hai Liu, College of Pharmacy, Gannan Medical University, Ganzhou, People’s Republic of China, Email liuhaiuser@163.com
Abstract: Photodynamic therapy (PDT), a precision modality based on photosensitizers, light, and oxygen, demonstrates unique advantages in lung cancer treatment. The limitations of traditional photosensitizers in clinical applications, including poor water solubility and insufficient targeting, have driven the development of nanotechnology and novel photosensitizers. Accordingly, this review elaborates on advanced strategies designed to enhance therapeutic specificity and efficacy, overcome the hypoxic tumor microenvironment (TME) and combat monotherapy resistance. These strategies include the design of various nanocarriers, active targeting ligands, novel energy transfer methods, as well as intelligent responsive systems and combination therapies. Nevertheless, despite abundant preclinical achievements, the clinical translation of nano-PDT formulations faces significant obstacles. Future efforts should focus on developing theranostic platforms to rigorously evaluate clinical safety and efficacy, enable precision treatment, and decipher immunological synergy.
Keywords: photodynamic therapy, nanomedicine, targeting ligands, responsive design, lung cancer